# US 2021/0230570 A1 · Modified factor ix polypeptides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0230570 A1
- Document ID: US20210230570A1
- Status: Published application
- Kind: A1
- Application number: 17/203,623
- Filed: 2021-03-16
- Published: 2021-07-29
- Earliest claimed: 2010-11-03
- Assignees: Catalyst Biosciences, Inc.
- Applicants: Catalyst Biosciences, Inc.
- Inventors: Edwin L. Madison; Christopher Thanos; Grant Ellsworth Blouse
- Web page: https://patentgrep.com/patent/US20210230570A1

## CPC

- C12N 9/644: {Coagulation factor IXa (3.4.21.22)}
- A61K 38/4846: {Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C12Y 304/21022: Coagulation factor IXa (3.4.21.22)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Modified Factor IX (FIX) polypeptides and uses thereof are provided. Nucleic acid molecules encoding modified factor IX (FIX) polypeptides and uses thereof also are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.

## Claims

### Claim 1

A modified Factor IX (FIX) polypeptide, comprising one or more amino acid modification(s) in an unmodified FIX polypeptide, wherein:
an amino acid modification corresponds to R318Y, R318E, R318F, or R318W, with reference to the sequence of amino acids set forth in SEQ ID NO:3;
corresponding amino acid residues are identified by alignment of the unmodified FIX polypeptide with the FIX polypeptide of SEQ ID NO:3;
the unmodified FIX polypeptide comprises a sequence of amino acids set forth in any of SEQ ID NOs: 2, 3, 20, or 325, or a sequence of amino acids having at least 95% sequence identity to the FIX polypeptide sequence set forth in any of SEQ ID NOs: 2, 3, 20, or 325, or a catalytically active fragment thereof; and
modifications are amino acid replacements, additions, or deletions, or any combination thereof.

### Claim 2 (depends on 1)

The modified FIX polypeptide of claim 1, that, when in active form (FIXa), exhibits increased resistance to antithrombin III and/or heparin, and/or one or both of increased catalytic activity and increased procoagulant activity, compared to the active form of the unmodified FIX polypeptide that does not contain the modification(s).

### Claim 3 (depends on 1)

The modified FIX polypeptide of claim 1, wherein the unmodified FIX polypeptide comprises the sequence of amino acids set forth in any of SEQ ID NOs: 2, 3, 20, or 325, or is unmodified activated FIX (FIXa), which consists of a light chain that consists of residues 1-14S, and a heavy chain that consists of residues 181-41S, of SEQ ID NO:3.

### Claim 4 (depends on 1)

The modified FIX polypeptide of claim 1, comprising the amino acid replacement corresponding to R318Y.

### Claim 5 (depends on 1)

The modified FIX polypeptide of claim 1, further comprising the amino acid replacements corresponding to replacements T343R, T343E or T343D.

### Claim 6 (depends on 1)

The modified FIX polypeptide of claim 1, further comprising an amino acid replacement at a residue corresponding to R338.

### Claim 7 (depends on 6)

The modified FIX polypeptide of claim 6, wherein the replacement at the residue corresponding to R338 corresponds to an amino acid replacement R338D or R338E.

### Claim 8 (depends on 7)

The modified FIX polypeptide of claim 7 that comprises the amino acid replacement R338E.

### Claim 9 (depends on 6)

The modified FIX polypeptide of claim 6, wherein the replacement at the residue corresponding to R338 is R338L.

### Claim 10 (depends on 1)

The modified FIX polypeptide of claim 1, comprising the amino acid replacements corresponding to R318Y/R338E.

### Claim 11 (depends on 7)

The modified FIX polypeptide of claim 7, further comprising an amino acid replacement corresponding to T343R.

### Claim 12 (depends on 1)

The modified FIX polypeptide of claim 1, wherein the unmodified FIX polypeptide comprises the sequence of amino acids set forth in SEQ ID NO:3 or SEQ ID NO:20.

### Claim 13 (depends on 1)

The modified FIX polypeptide of claim 1, comprising amino acid replacements corresponding to R318Y/T343R.

### Claim 14 (depends on 1)

The modified FIX polypeptide of claim 1, further comprising an amino acid replacement at the residue corresponding to E410, wherein the replacement is N or S.

### Claim 15 (depends on 14)

The modified FIX polypeptide of claim 14 that comprises amino acid replacements corresponding to R318Y/E410N.

### Claim 16 (depends on 1)

The modified FIX polypeptide of claim 1 that comprises an amino acid replacement corresponding to R318Y and one or more amino acid replacements at an amino acid residue corresponding to a residue selected from among 338, 343, 403, and 410.

### Claim 17 (depends on 16)

The modified FIX polypeptide of claim 16, comprising an amino acid replacement corresponding to R318Y, and one or more replacements selected from among R338E, T343R, R403E, and E410N.

### Claim 18 (depends on 1)

The modified FIX polypeptide of claim 1 that comprises amino acid replacements corresponding to replacements selected from among R318Y/R338E/R403E/E410N, Y155F/K247N/N249S/R318Y/R338E, R318Y/T343R/E410N, Y155F/R318Y/R338E/R403E, R318Y/R338E/R403E, R318Y/R338E/E410N, K228N/R318Y/E410N, R318Y/R403E/E410N, D203N/F205T/R318Y/E410N, A103N/N105S/R318Y/R338E/R403E/E410N, D104N/K106S/R318Y/R338E/R403E/E410N, K228N/R318Y/R338E/R403E/E410N, I251S/R318Y/R338E/R403E/E410N, D104N/K106S/I251S/R318Y/R338E/R403E/E410N, D104N/K106S/R318Y/R338E/E410N, I251S/R318Y/E410N/R338E, D104N/K106S/I251S/R318Y/R338E/E410N, A103N/N105S/K247N/N249S/R318Y/R338E/R403E/E410N, D104N/K106S/K247N/N249S/R318Y/R338E/R403E/E410N, K228N/K247N/N249S/R318Y/R338E/R403E/E410N, A103N/N105S/Y155F/R318Y/R338E/R403E/E410N, D104N/K106S/Y155F/R318Y/R338E/R403E/E410N, Y155F/K228N/R318Y/R338E/R403E/E410N, Y155F/I251S/R318Y/R338E/R403E/E410N, K247N/N249S/R318Y/R338E/R403E/E410N, Y155F/R318Y/R338E/R403E/E410N, K247N/N249S/R318Y/R338E/E410N, Y155F/R318Y/R338E/E410N, Y155F/K247N/N249S/R318Y/R338E/E410N, R318Y/R338E/R403E/E410S, R318Y/R338E/R403E/E410N/T412V, R318Y/R338E/R403E/E410N/T412A, R318Y/R338E/R403E/T412A, R318Y/R338E/E410S, R318Y/R338E/T412A, R318Y/R338E/E410N/T412V, D85N/K228N/R318Y/R338E/R403E/E410N, N260S/R318Y/R338E/R403E/E410N, R318Y/R338E/N346D/R403E/E410N, Y155F/R318Y/R338E/N346D/R403E/E410N, K247N/N249S/N260S/R318Y/R338E/R403E/E410N, D104N/K106S/N260S/R318Y/R338E/R403E/E410N, Y155F/N260S/R318Y/R338E/R403E/E410N, D104N/K106S/Y155F/K247N/N249S/R318Y/R338E/R403E/E410N, D104N/K106S/K228N/K247N/N249S/R318Y/R338E/R403E/E410N, Y155F/K228N/K247N/N249S/R318Y/R338E/R403E/E410N, Y155F/K247N/N249S/N260S/R318Y/R338E/R403E/E410N, R318Y/R338E/Y345A/R403E/E410N, K228N/I251S/R318Y/R338E/R403E/E410N, R318Y/R338E/Y345A/N346D/R403E/E410N, Y155F/K247N/N249S/R318Y/R338E/R403E, K247N/N249S/R318Y/R338E/R403E, Y155F/K247N/N249S/R318Y/R403E/E410N, K247N/N249S/R318Y/R403E/E410N, R318Y/T343R/R403E/E410N, Y155F/K228N/I251S/R318Y/R338E/R403E/E410N, Y155F/K247N/N249S/R318Y/R403E, Y155F/K247N/N249S/R318Y/E410N, Y155F/K247N/N249S/R318Y/T343R/R403E/E410N, K247N/N249S/R318Y/T343R/R403E/E410N, Y155F/K247N/N249S/R318Y/T343R/R403E, K247N/N249S/R318Y/T343R/R403E, Y155F/K247N/N249S/R318Y/T343R/E410N, K247N/N249S/R318Y/T343R/E410N, Y155F/R318Y/T343R/R403E, Y155F/R318Y/T343R/E410N, Y155F/K247N/N249S/R318Y/T343R, Y155F/K247N/N249S/R318Y/R338E/R403E/E410N, K228N/K247N/N249S/R318Y/T343R/R403E/E410N, and Y155F/R318Y/R403E/E410N.

### Claim 19 (depends on 1)

The modified FIX polypeptide of claim 1, comprising amino acid replacements corresponding to R318Y/R338E/R403E/E410N, Y155F/K247N/N249S/R318Y/R338E, R318Y/T343R/E410N, or Y155F/R318Y/R338E/R403E.

### Claim 20 (depends on 1)

The modified FIX polypeptide of claim 1, wherein the unmodified FIX polypeptide is a mature FIX polypeptide of SEQ ID NO:3 or SEQ ID NO:20.

### Claim 21 (depends on 1)

The modified FIX polypeptide of claim 1 that is an activated FIX (FIXa) polypeptide.

### Claim 22 (depends on 1)

The modified FIX polypeptide of claim 1, comprising a sequence of amino acids set forth in any of SEQ ID NOs: 121, 122, 153, 156, 161, 166, 169-173, 188, 219-226, 232-244, 249-258, 260, 264-267, 326-331, 333, 334, 336-342, 345-350, 353-360, 366, 368, 369, 372-375, 378-381, 383-386, 393-395, 397, 398, 403-408, 410, 411, 413, and 414, or an activated form thereof.

### Claim 23 (depends on 1)

The modified FIX polypeptide of claim 1 that is a mature polypeptide.

### Claim 24 (depends on 1)

The modified FIX polypeptide of claim 1 that is a two-chain polypeptide.

### Claim 25 (depends on 1)

The modified FIX polypeptide of claim 1 that is a single-chain polypeptide.

### Claim 26 (depends on 1)

The modified FIX polypeptide of claim 1 that is active or activated.

### Claim 27 (depends on 1)

The modified FIX polypeptide of claim 1 that comprises one or more chemical modification(s) or post-translational modification(s).

### Claim 28 (depends on 27)

The modified FIX polypeptide of claim 27, wherein the modification is selected from among glycosylation, carboxylation, hydroxylation, sulfation, phosphorylation, albumination, and conjugation to a polyethylene glycol (PEG) moiety.

### Claim 29 (depends on 1)

The modified FIX polypeptide of claim 1, comprising up to 10 amino acid modifications, compared to the unmodified FIX polypeptide of SEQ ID NO:2 or SEQ ID NO:3.

### Claim 30 (depends on 1)

The modified FIX polypeptide of claim 1, comprising modifications that introduce and/or eliminate one or more glycosylation sites compared to the unmodified FIX polypeptide of SEQ ID NO: 2, 3, 20, or 325, or compared to the unmodified FIXa polypeptide that consists of a light chain that consists of residues 1-14S, and a heavy chain that consists of residues 181-41S, of SEQ ID NO:3.

### Claim 31 (depends on 1)

The modified FIX polypeptide of claim 1, comprising the amino acid replacements R318Y/R338E/T343R, wherein:
the unmodified FIX polypeptide consists of a sequence of amino acids set forth in any of SEQ ID NOs: 2, 3, 20, or 325; or
the unmodified FIX is a FIXa that consists of a light chain that consists of residues 1-14S, and a heavy chain that consists of residues 181-41S, of SEQ ID NO:3.

### Claim 32 (depends on 1)

A nucleic acid molecule, comprising a sequence of nucleotides encoding the modified FIX polypeptide of claim 1.

### Claim 33 (depends on 30)

A vector, comprising the nucleic acid molecule of claim 30.

### Claim 34 (depends on 33)

The vector of claim 33, wherein the vector is a prokaryotic vector, a viral vector, or a eukaryotic vector.

### Claim 35 (depends on 33)

The vector of claim 33, wherein the vector is a viral vector selected from among an adenovirus, an adeno-associated virus, a retrovirus, a herpes virus, a lentivirus, a poxvirus, and a cytomegalovirus.

### Claim 36 (depends on 33)

A cell, comprising the vector of claim 33.

### Claim 37 (depends on 36)

The cell of claim 36, that is a eukaryotic cell.

### Claim 38 (depends on 37)

The cell of claim 37, wherein the eukaryotic cell is a mammalian cell.

### Claim 39 (depends on 1)

A pharmaceutical composition, comprising the modified FIX polypeptide of claim 1 in a pharmaceutically acceptable vehicle.

### Claim 40 (depends on 1)

A method of treatment of a disease or condition, comprising administering the modified FIX polypeptide of claim 1, wherein the disease or condition to be treated is selected from among blood coagulation disorders, hematologic disorders, hemorrhagic disorders, hemophilias, and bleeding disorders.

### Claim 41 (depends on 32)

A method of treatment of a disease or condition, comprising administering the nucleic acid molecule of claim 32, or a vector comprising the nucleic acid molecule, wherein the disease or condition to be treated is selected from among blood coagulation disorders, hematologic disorders, hemorrhagic disorders, hemophilias, and bleeding disorders.

### Claim 42 (depends on 40)

The method of claim 40, wherein the disease or condition is a hemophilia.

### Claim 43 (depends on 41)

The method of claim 41, wherein the disease or condition is a hemophilia.
